BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27793878)

  • 1. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
    Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
    Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
    Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
    BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
    Xu Y; Fulciniti M; Samur MK; Ho M; Deng S; Liu L; Wen K; Yu T; Chyra Z; Dereibal S; Zhang L; Yao Y; Chakraborty C; Morelli E; Li N; Lopez MA; Perini T; Mu S; An G; Alonso R; Bianchi G; Tai YT; Anderson KC; Qiu L; Munshi NC
    Blood; 2020 Jul; 136(4):468-479. PubMed ID: 32187357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
    Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
    Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
    He Y; Wang S; Tong J; Jiang S; Yang Y; Zhang Z; Xu Y; Zeng Y; Cao B; Moran MF; Mao X
    J Biol Chem; 2020 Feb; 295(7):2084-2096. PubMed ID: 31822558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
    Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
    J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
    Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
    Nian F; Zhu J; Chang H
    Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
    Morito N; Yoh K; Maeda A; Nakano T; Fujita A; Kusakabe M; Hamada M; Kudo T; Yamagata K; Takahashi S
    Cancer Res; 2011 Jan; 71(2):339-48. PubMed ID: 21224354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis.
    Wang S; Juan J; Zhang Z; Du Y; Xu Y; Tong J; Cao B; Moran MF; Zeng Y; Mao X
    Cell Death Dis; 2017 Sep; 8(9):e3058. PubMed ID: 28933784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
    Polusani SR; Cortez V; Esparza J; Nguyen HN; Fan H; Velagaleti GVN; Butler MJ; Kinney MC; Oyajobi BO; Habib SL; Asmis R; Medina EA
    Int J Cancer; 2021 Jun; 148(12):3032-3040. PubMed ID: 33521927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
    Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
    Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.
    Sun T; Xu Y; Xu Z; Cao B; Zhang Z; Wang Q; Kong Y; Mao X
    Cell Commun Signal; 2021 Feb; 19(1):24. PubMed ID: 33627137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.